We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Revisiting the Technical Validation of Tumour Biomarker Assays: How to Open a Pandora's Box
News

Revisiting the Technical Validation of Tumour Biomarker Assays: How to Open a Pandora's Box

Revisiting the Technical Validation of Tumour Biomarker Assays: How to Open a Pandora's Box
News

Revisiting the Technical Validation of Tumour Biomarker Assays: How to Open a Pandora's Box

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Revisiting the Technical Validation of Tumour Biomarker Assays: How to Open a Pandora's Box"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Abstract

A tumour biomarker is a characteristic that is objectively measured and evaluated in tumour samples as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. The development of a biomarker contemplates distinct phases including discovery by hypothesis generating preclinical or exploratory studies, development and qualification of the assay for the identification of the biomarker in clinical samples, and validation of its clinical significance. Although guidelines for the development and validation of biomarkers are available, their implementation is challenging, owing to the diversity of biomarkers being developed. The term validation undoubtedly has several meanings, however in the context of biomarker research, a test may be considered valid if it is 'fit for purpose'. In the process of validation of a biomarker assay, a key point is the validation of the methodology.

The article is published online in BMC Medicine and is free to access.

Advertisement